Trials / NCT06628947
A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
Recruiting now Phase 2 Optogenetics
- Sponsor
- Kiora Pharmaceuticals, Inc.
- Treatment
- Placebo (Sterile Saline or Balanced Salt Solution); 100 μg KIO-301; 50 μg KIO-301
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 36 participants
- Started
- 2025-08-29
- Main results expected
- 2027-08
- Results posted
- Not yet
- Record last updated
- 2026-06-18
What the study is testing
The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injection bilaterally every 6 weeks in patients with late-stage retinitis pigmentosa (RP).
Late-stage RP patients will include those patients with No Light Perception (NLP), or Low Vision (LV).
Where it runs
Australia (5)
- Save Sight Institute, Sydney, New South Wales (recruiting now)
- Queensland Eye Institute, Woolloongabba, Queensland (recruiting now)
- Royal Adelaide Hospital, Adelaide, South Australia (recruiting now)
- Cerulea Clinical Trials, East Melbourne, Victoria (recruiting now)
- Lions Eye Institute, Nedlands, Western Australia (recruiting now)